Akebia Therapeutics, Inc. The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the Eastern District of New York on behalf of investors who purchased Akebia Therapeutics, Inc. (NASDAQ: AKBA) securities between June 28, 2018 and September 2, 2020.
According to the Akebia lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (i) the Company’s lead investigational product candidate, vadadustat, was not as safe in treating non-dialysis dependent chronic kidney disease patients with anemia as defendants had represented; (ii) as a result, defendants overstated the clinical prospects of a Phase 3 clinical program for vadadustat; (iii) accordingly, defendants also overstated vadadustat’s overall commercial and regulatory prospects; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.
“Akebia Therapeutics, Inc.”
If you suffered a loss in Akebia you have until May 13, 2022 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
To receive more information, please fill out the form.